interleukin-2


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to interleukin-2: Proleukin

in·ter·leu·kin-2

 (ĭn′tər-lo͞o′kĭn-to͞o′)
n.
A cytokine that is released by T cells in response to an antigen and regulates the proliferation and differentiation of natural killer cells, B cells, and other T cells. It has been used experimentally to treat cancer.
References in periodicals archive ?
The company stated the PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), is authorised for the treatment of high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Interleukin-2 (IL-2), which plays a critical role in the maintenance of immune homeostasis, is deficient in SLE.
The report provides comprehensive information on the Interleukin-2 Receptor Subunit Alpha (IL-2 Receptor Subunit Alpha or TAC Antigen or p55 or CD25), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Interleukin-2 (IL-2) enhances overall immune function, most notably by enhancing natural killer cell activity.
The soluble interleukin-2 receptor (sIL-2R) is released along with interleukin-2 from activated T lymphocytes.
Researchers experimented with 185 patients with metastatic melanoma, who were assigned to either a combination of the peptide vaccine, which is a small portion of protein that exists on the surface of the melanoma cancer cells, and Interleukin-2, or a high dose of Interleukin-2 alone.
Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals.
The objective of this study was to examine the potential usefulness of cervicovaginal interleukin-6 (IL-6), tumor necrosis factor-[alpha] (TNF[alpha]), and interleukin-2 receptor (IL-2R) in the prediction of delivery in symptomatic women within 14 days of testing.
For example, while the FDA dithered over approving the drug Interleukin-2 (already approved in at least nine other countries), some 25,000 Americans died of kidney cancer.
Patients receiving antibodies against the interleukin-2 receptor had no increase in the level of infection or malignancy after 1year, compared with those given placebo.
* ACTS A5132: Using interleukin-2 (an immune booster) with up to 3 interruptions of anti-HIV treatment, researchers in this study will look at whether immune reactions specifically against HIV can be enhanced.